Additionally, a patient with HER2 2+ advanced gastric cancer and systemic metastasis, who had failed first-line treatment, achieved a 6-month PFS after receiving Disitamab Vedotin (Dai et al., 2022). The gene discussed is ERBB2; the disease is gastric cancer.